Oscar Health’s Insider Dealings Signal Cautious Confidence Amid a Volatile Market

Insider Activity Highlights a Strategic Shift at Oscar Health

Oscar Health Inc.’s latest director‑dealing filing on March 2, 2026 shows President Liang Janet of Oscar Insurance buying 106,458 shares of Class A common stock under a restricted‑stock‑unit (RSU) program, while selling 7,453 shares at a Rule 10b‑5 instruction to cover tax withholding on earlier awards. The RSU purchase is a forward‑looking sign: the shares vest quarterly over the next 12 months, beginning June 1, 2026, and reflect confidence in the company’s technology‑driven growth trajectory. The simultaneous sale is routine, clearing the tax burden that often accompanies RSU vesting. For investors, the net effect is a modest increase in the number of shares held by a key executive, suggesting a long‑term commitment to Oscar’s valuation upside.

Investor Implications in a Volatile Market

With the stock currently trading near $13.70—well below its 52‑week high of $23.80—insider purchases like Janet’s can provide a morale boost in an otherwise bearish environment. The company’s negative P/E (-8.14) indicates ongoing operating losses, yet its price‑to‑book of 4.15 points to potential upside if the platform gains traction. The sizable buy by CEO Mark Bertolini (955,556 shares) and the layered transactions by other C‑suite members (e.g., CFO Richard Scott’s 134,847‑share buy and subsequent sell) illustrate a pattern of selective accumulation followed by periodic liquidity events. Such behavior signals that senior management is balancing short‑term cash needs with a belief that the business model will eventually yield sustainable earnings.

Liang Janet: A Profile of Cautious Commitment

Janet’s historical trade record—two large sales in June and September 2025, each for ~7,200 shares at $13.80–$16.66—demonstrates a conservative approach to liquidity. Her most recent RSU purchase aligns with this pattern: she prefers to lock in equity that vests gradually, thereby mitigating market timing risk while maintaining a vested interest in Oscar’s long‑term success. Unlike some insiders who aggressively accumulate shares, Janet’s actions suggest a measured, risk‑aware stance. The timing of the current purchase (just after a modest 0.10% price uptick and amid a high social‑media buzz of 704 %) also indicates that she is responsive to market sentiment, using favorable conditions to strengthen her stake.

Broader Insider Activity: A Mixed Signals Snapshot

The broader insider activity on March 2, 2026 shows a mix of buys and sells across the executive team. While CFO Scott and CTO Mario both sold ~19,000 shares at $13.39, their concurrent purchases of over 130,000 shares each reveal a net position shift toward ownership. Legal Officer Adam’s pattern mirrors this—selling 18,710 shares at $13.39 while buying 67,424 shares—suggesting a strategic repositioning rather than an exit. CEO Bertolini’s massive buy, combined with a 0.00‑price sale of the same shares (likely a vesting event), underscores his long‑term belief in Oscar’s upside.

What Does This Mean for the Future?

For investors, the insider trend—moderate purchases paired with routine liquidity sales—suggests confidence without overexposure. The RSU program’s vesting schedule introduces a predictable dilution curve that may soften future share supply. Meanwhile, the company’s positive weekly gain (16.22%) and strong monthly momentum (7.5%) hint at a potential rebound if the platform’s value proposition resonates with members and insurers alike. The key question remains: can Oscar Health translate its technology promise into profitable operations? Insider actions provide a cautiously optimistic signal, but the ultimate test will be in earnings growth and member acquisition in the coming quarters.